Diagnostics Stories

Dr. Tushar Jaiprakash Semwal graduated from the Pravara Institute of Medical Sciences. In May 2012, at Pravara Rural University, Loni (M.H.) awarded him an MBBS degree and a year of rotating internship. In August 2017, he received his doctor of medicine in interventional radio diagnosis from the Himalayan Institute of Medical Sciences, Swami Rama University, Dehradun, Uttarakhand.

An antigen is any substance that may be specifically bound by an antibody molecule or T cell receptor. Antibodies can recognize as antigens almost every kind of biologic molecule, including simple intermediary metabolites, sugars, lipids, autacoids, and hormones, as well as macromolecules such as complex carbohydrates, phospholipids, nucleic acids, and proteins. This is in contrast to T cells, which mainly recognize peptides. Creative Diagnostics offers hapten for your research. http://www.creative-diagnostics.com/Hapten.htm

The Global Point-of-care Molecular Diagnostics Industry is on track for a significant surge, fueled by the increasing demand for faster and more convenient diagnostic solutions. According to a recent analysis by Future Market Insights (FMI), the market is projected to reach an impressive US$11.1 billion by 2033, reflecting a remarkable growth trajectory from its estimated valuation of US$4.4 billion in 2023. This phenomenal rise signifies a Compound Annual Growth Rate (CAGR) of 9.7% over the next decade, highlighting the growing adoption of point-of-care molecular diagnostics across various healthcare settings.

The Global Sepsis Diagnostics Industry is on the brink of an unprecedented growth phase, with a projected Compound Annual Growth Rate (CAGR) of 8.1% between 2023 and 2033. Valued at US$ 561.2 million in 2023, the market is anticipated to soar beyond US$ 1.2 billion by the close of 2033.